Waning immunity and booster responses in nursing and medical technology students who had received plasma-derived or recombinant hepatitis B vaccine during infancy

American Journal of Infection Control

Volumn 39, Issue 5, 2011, Pages 408-414

  Lin, Ching Chiang ^a,b,c   Yang, Chun Yuh ^a   Shih, Ching Tang ^b   Chen, Bai Hsiun ^d   Huang, Yeou Lih ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anamnestic response; booster; hepatitis B

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; DOSE RESPONSE; FEMALE; HEPATITIS B; HUMAN; IMMUNITY; INFANCY; INFECTION CONTROL; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; NURSING STUDENT; SEROCONVERSION; SEROPREVALENCE; TAIWAN;

ADOLESCENT; BODY MASS INDEX; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; SEROEPIDEMIOLOGIC STUDIES; STUDENTS, MEDICAL; TAIWAN; VACCINATION; VACCINES, DNA;

EID: 79957882838     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2010.07.010     Document Type: Article

References (39)

1. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
3. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168-74.
4. WHO global immunization data. Available from: http://www.who.int/ immunization-monitoring/data/en/. Accessed July 7, 2010.
5. Huang KY, Lin SR. Nationwide vaccination: a success story in Taiwan. Vaccine 2000;18:S35-8.
6. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126-35.
7. Lin DB, Wang HM, Lee YL, Ling UP, Changlai SP, Chen CJ. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 1998;16:1683-7.
8. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: 10 years of mass vaccination in Taiwan. JAMA 1996;276:906-8.
9. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007;132:1287-93.
10. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52.
11. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.
12. Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995;126:716-21.
13. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003;187:134-8.
14. Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. Eighteen-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004;2:941-5. (Pubitemid 39335802)
15. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008;197: 1419-26.
16. Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine 2007;25:7160-7. (Pubitemid 47464669)
17. Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of central Taiwan. Vaccine 2009;27:1858-62.
18. Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007;25:8085-90.
19. Lu SN, Chen CH, Chen TM, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B virus infection in adolescents in a rural township - 15 years subsequent to mass hepatitis B vaccination in Taiwan. Vaccine 2006; 24:759-65.
20. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-5.
21. Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40:1-25.
22. Holton D. Revised guidelines for booster vaccination against hepatitis B. Can Med Assoc J 1992;147:1029-32.
23. Thompson SC, Norris M. Hepatitis B vaccination of personnel employed in Victorian hospitals: are those at risk adequately protected? Infect Control Hosp Epidemiol 1999;20:51-4.
24. Barash C, Conn MI, DiMarino AJ Jr, Marzano J, Allen ML. Serologic hepatitis B immunity in vaccinated health care workers. Arch Intern Med 1999;159:1481-3. (Pubitemid 29302889)
25. Davies GR, Porra M. The need for post-vaccination serology and the timing of booster vaccinations against hepatitis B in dental health care workers. Aust Dent J 1994;39:238-41.
26. Taiwan CDC updates news. Available from: http://www.cdc.gov.tw/content. asp?cuitem521733&mp51. Accessed July 7, 2010.
27. Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM, et al.Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004;40:1415-20.
28. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007;120: e373-81.
29. Lin CC, Chang CK, Huang YL, Tseng HF. Low seroprevalence of hepatitis B surface antibody among nursing students in Taiwan: an implication for boosting. Vaccine 2007;25:8508-11.
30. Lin HH, Wang LY, Hu CT, Huang SC, Huang LC, Lin SS, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003;69:471-4. (Pubitemid 36249859)
31. Su FH, Chen JD, Cheng SH, Lin CH, Liu YH, Chu FY. Seroprevalence of hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national hepatitis-B vaccination program. J Med Virol 2007;79:128-43.
32. Koff RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 2002;20:3695-701. (Pubitemid 35223399)
33. Pongpipat D, Suvatte V, Assateerawatts A. Hepatitis B immunization in high-risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. Asian Pac J Allergy Immunol 1989;7:37-40. (Pubitemid 19176961)
34. Fitzsimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B mutants. Vaccine 2005;23:4158-66. (Pubitemid 40814591)
35. Banatvala JE, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2001;19:877-85.
36. Wang LY, Lin HH. Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. J Hepatology 2007;46: 1018-25. (Pubitemid 46680359)
37. Shiao J, Guo L, McLaws ML. Estimation of the risk of bloodborne pathogens to health care workers after a needlestick injury in Taiwan. Am J Infect Control 2002;30:15-20. (Pubitemid 34155277)
38. John TJ, Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? J Gastroenterol Hepatol 2005; 20:5-10.
39. Yoshida T, Saito I. Hepatitis B booster vaccination for health care workers. Lancet 2000;355:1464-6.